Relapsed/Refractory Multiple Myeloma (and other Pfizer grants)

Filter list by selecting Oncology for Focus Area
Brief Description

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

The following grants are available:

Relapsed/Refractory Multiple Myeloma
View RFP (PDF)
Application due: August 31, 2021

PCF-Pfizer-Myovant Relugolix Challenge Awards
View RFP (PDF)
Application due: August 16, 2021

A Phased Approach to Understanding and Addressing Healthcare Disparities for People of Color
View RFP (PDF)
Application due: August 4, 2021